NCP Flanders
choose your programme
Horizon Europe

Horizon Europe is the main Research and Innovation Funding Programme of the European Commission.

Horizon 2020

Horizon 2020 is the previous Funding Programme. There are no longer calls, but projects can run until 2024.

Digital Europe

Digital Europe is a Funding Programme focused on bringing digital technology to businesses, citizens and administrations.

Other EU Funding

There are many other relevant EU funding programmes, managed by several agencies and directorates.

COST

COST (Cooperation in Science and Technology) is a EU funded programme that provides funding for research networks. COST's mission is to strengthen Europe in scientific and technological research through the support of European cooperation and interaction between European researchers.

Your NCP contact for this programme

Image of Man Hei To

Man Hei To

manhei.to@fwo.be

+32 2 550 15 55

About this programme

COST plays an important role in the development of the European research area. COST's mission is to strengthen Europe in scientific and technological research through the support of European cooperation and interaction between European researchers.

Under Horizon Europe COST will be fully funded by the Widening and ERA part and is one of the widening actions to help EU countries that are lagging behind to stimulate their participation in Horizon Europe through scientific networking.

These networks, in the form of COST Actions, can be in any scientific field and are open to all type of actors (academia, public institutions, SMEs, Companies, etc.). A typical COST Action runs for four years and has an average budget of 134,500 EUR per year.

The funding is limited to networking activities (meetings, conferences, seminars, workshops) and the organisation of exchange activities (scientific exchanges of short duration, training schools, publications and dissemination activities). The actual research is funded via other (national or regional) channels.

There are mainly two ways to engage with COST:

  • you can either join an already existing COST Action. Click here to have an overview of the existing COST Actions. There are several ways to join a COST Action: participating in the management committee, working groups or other activities of the COST Action. More information on how you can join a new or running COST Action can be found here.
  • you can create a new COST Action. New ideas for COST Actions can be submitted through the COST Open Call, that is organized once a year.

 

In Flanders, FWO is the first Contact Point for any questions related to the COST Programme. For more information on COST please visit the FWO website.

Click to read more 
Hide text 

Latest news

Upcoming events

No events that are specifically related to COST were found. Check the full calendar.

Infosheets

Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.

    No infosheets available for this domain

Related links

Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.

Documents

Documents contain additional information related to this programme, and are similar to related links.

    No documents available for this domain

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.